In this webinar, attendees will learn about orthogonal peptide purity and how to remove bottlenecks in peptide purification with PurePep® EasyClean (PEC) Kits and PEC-grade peptides.
During the early stages of drug development, from screening to lead optimization, or more generally, when researchers employ multiple peptides (or peptide libraries) in valuable assays – they often use crude peptides. This is because the purification throughput is difficult, time-consuming and costly to achieve with chromatography. However, this imposes a significant risk to assay reliability and causes a waste of resources and time on the way to important results. Reducing the peptide selection to match the potential throughput of chromatography may result in missing promising candidates.
PEC enables simple, fast and sustainable access to purified peptides at high-throughput and various scales with best-in-class purification kits to fill this gap. The resulting PEC-grade purity is the spot-on quality for the research and preclinical assays because error-causing impurities are removed orthogonally in a simple protocol.
Register for this webinar to learn about orthogonal peptide purity and purification, understand the basic principles of the PurePep EasyClean technology and how to start with it easily to accelerate time to the best possible result during peptide research and drug development.
Dominik Sarma, Sr. Market Manager, Gyros Protein Technologies AB
Dominik Sarma did his PhD at the Humboldt-University of Berlin in the field of advanced analytical materials. He co-founded the Berlin-based peptide company Belyntic in 2018. Belyntic developed the first universally applicable catch-and-release peptide purification technology Peptide EasyClean (PEC). After the acquisition of PEC by Gyros Protein Technologies (GPT) in November 2022, Dominik joined GPT as Sr Market Manager, responsible for the marketing and sales strategy of the PEC offer, including Kits and Services.
Robert Zitterbart, Director R&D PurePep EasyClean Solutions (PECS), Gyros Protein Technologies AB
Robert Zitterbart also carried out research for his chemistry diploma thesis on enantioselective natural product synthesis under the supervision of Prof K. Peter C. Vollhardt at the University of California, Berkeley and graduated in February 2011 from Humboldt-University, Berlin. Thereafter he complete his PhD research under the supervision of Prof Oliver Seitz, specializing in the chemical synthesis of protein-domain-arrays.
Together with three other chemists and one economist he started the spin-off EnviroPep at Humboldt-University, Berlin in 2016, and for the next 20 months he worked to develop the Peptide EasyClean (PEC) technology to marketable products. In 2018 Robert co-founded Belyntic GmbH and was Head of R&D and co-CEO developing linker systems for the PEC technology to purify and modify synthetic peptides. In November 2022 PEC was acquired by Gyros Protein Technologies and he is now Director R&D of PurePep EasyClean Solution (PECS) in Berlin/Teltow.
Who Should Attend?
- Drug manufacturers
- Site and project managers
- Students who work with multiple synthetic peptides or peptide libraries
What You Will Learn
- Understanding orthogonal purity and purification
- Basic principles of catch & Release purification with PurePep® EasyClean (PEC) Kits
- Introduction to PEC-grade peptides and PEC-grade libraries
- Use cases for PEC-grade peptides during drug development
Gyros Protein Technologies
Gyros Protein Technologies enables peptide and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the PurePep® Chorus, Symphony® X, and PurePep®Sonata®+. The PurePep® EasyClean (PEC) technology complements the PurePep® portfolio with Kits and Services for peptide purification and modification. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides up- and downstream. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab® xPand, Gyrolab® xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics. Gyros Protein Technologies is part of the Biopharmaceutical Division of Mesa Laboratories, Inc